Latest Transfusion-associated graft versus host disease Stories

JERUSALEM, Oct. 24, 2012 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that its portfolio company Enlivex has completed a clinical trial and is reporting positive results that indicate efficacy and safety in its treatment for recipients of bone marrow transplants from...

New research in mice published in the Journal of Leukocyte Biology suggests that the platelet activating factor receptor plays a role in graft-versus-host disease, a major complication of bone marrow transplants A new discovery in mice may lead to new treatments that could make bone marrow transplants more likely to succeed and to be significantly less dangerous. According to new research findings published in the Journal of Leukocyte Biology (https://www.jleukbio.org) Brazilian scientists...

Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant. The study, led by researchers with the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), used an animal model and tissues from human patients to show that high levels, or over-expression, of a...

MARLBOROUGH, Mass. and WILMINGTON, Del., Feb. 13, 2012 /PRNewswire/ -- Ashland Specialty Ingredients, a commercial unit of Ashland Inc. (NYSE: ASH), has chosen Web Industries, Inc., a global leader in custom manufacturing and development services for flexible materials, to manufacture its Rad-Sure line of blood irradiation indicators. This partnership will allow Ashland to see increased production yields and reduced defect rates over the lifespan of the contract for the...

New approach redirects lymphocytes from harming vital organs, without dangers of immunosuppression An HIV drug that redirects immune cell traffic appears to significantly reduce the dangerous complication graft-versus-host disease (GvHD) in blood cancer patients following allogeneic stem cell transplantation (ASCT), according to new research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 53rd American Society of Hematology Annual...

PRINCETON, N.J., Dec. 12, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC BB: SNGX), a development stage biopharmaceutical company, announced the publication of results from its investigator-initiated Phase 2 "proof-of-concept" exploratory clinical trial of orBec® for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation...

Study has implications for treatment of other immune-mediated disorders In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound. The phase I study, published in the Dec. 1 issue of the New England Journal of Medicine, involved allogeneic (donor)...

NEW YORK, Aug. 17, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed by the Hadassah University Hospital, Israel's foremost medical research center, announced that its portfolio company Enlivex Therapeutics (92% owned by Hadasit Bio) has completed the recruitment of three out of four groups in its Phase I / II clinical trial using its treatment for the reduction of graft versus...

HOUSTON, March 25, 2011 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced that the Company received notice of a $5.7 million company commercialization award from the Cancer Prevention and Research Institute of Texas ("CPRIT"). Bellicum was the only company recommended for funding in this second round of the commercialization award program. The award will fund personnel, manufacturing, and clinical testing of Bellicum's CaspaCIDe(TM) therapy, which promises to substantially...

For blood cancer patients at high risk of relapse, hematopoietic stem cell transplantation (HSCT), the transplantation of blood-forming stem cells, is one of best options for treatment and a potential cure. Unfortunately, the most common complication of HSCT is graft-versus-host disease (GVHD), a serious and often deadly post-transplant complication that occurs when the newly transplanted donor cells recognize the recipient's own cells as foreign and react by attacking the cells in the...